Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00926731 · ClinicalTrials.gov registry record · Phase 1

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

A Phase 1 study of Acute Myeloid Leukemia, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
4
Enrollment target
4
Study locations

NCT00926731: Completed Phase 1 study of Acute Myeloid Leukemia, sponsored by AstraZeneca.

NCT00926731 is a Phase 1 study of Acute Myeloid Leukemia that has completed, run by AstraZeneca. The registered enrollment target is 4 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00926731, a Phase 1 study of Acute Myeloid Leukemia, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
4 participants
Enrollment target
4
Study locations

Study Summary

A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG AZD1152
  • DRUG LDAC (low dose cytosine arabinoside)

Study Locations (4)

Other

  • Research Site - Le Chesnay
  • Research Site - Villejuif

Ohio

  • Research Site - Cleveland

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2009-06
Est. Completion 2011-05
Phase Phase 1
AstraZeneca

1,285 total trials

What the finished NCT00926731 record still lists

NCT00926731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which AZD1152 is the first listed.

NCT00926731 reports a single indexed study location in Other, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT00926731 about?

NCT00926731 is a clinical study titled "Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)". A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.

What is the current status of trial NCT00926731?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-06. Estimated completion is 2011-05.

What conditions does trial NCT00926731 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT00926731?

The interventions under investigation include: AZD1152 (DRUG), LDAC (low dose cytosine arabinoside) (DRUG).

Who is sponsoring clinical trial NCT00926731?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00926731 being conducted?

This trial has 4 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00926731's enrollment target sits among peer trials

4 306th of 306 higher than 1 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00926731, the US trial registry maintained by the National Library of Medicine. NCT00926731 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.